Mesothelioma Clinical Trial Combines Immunotherapy Drugs
Dr. Tawee Tanvetyanon at the Moffitt Cancer Center in Tampa rarely sounds this enthused about the future prospects for patients with pleural mesothelioma. Finally, he has something promising to offer. Tanvetyanon is the principal investigator of a much-anticipated phase II clinical trial involving an immunotherapy drug combination with considerable potential for extending survival. “This is exciting. We now can offer something with realistic hope,” he told Asbestos.com. “We haven’t had anything like this for mesothelioma in a long time. I really look forward to speaking with these patients now.” Moffitt recently became the first multidisciplinary specialty center to begin enrolling mesothelioma patients in a trial that will evaluate the efficacy of combining CRS-207 with pembrolizumab — two immunotherapy drugs that already showed effectiveness individually — in a second-line setting. “Of course, the hope is that we see significant tumor shrinkage. We already know, we have data, that each of these agents will work in a number of patients,” Tanvetyanon said. “There is good reason to think that combining the two will work even better, a one-plus-one-equals-three synergy.” Drug Companies Working Together Two competing pharmaceutical companies have worked together to make this latest, anti-cancer combination a reality for mesothelioma patients. Aduro Biotech, based in Berkeley, California, produces CRS-207, which us...
Publication date: Available online 20 October 2018Source: Urology Case ReportsAuthor(s): Y. Ayari
Authors: Fisichella R, Benfatto S, Berretta S PMID: 30338830 [PubMed - in process]
CONCLUSIONS: MiR-124 down-regulation was associated with renal cancer cell OS-RC-2 invasion enhancement. Over-expression of miR-124 attenuated OS-RC-2 cell invasion by down-regulating STAT3 and MMP-9. PMID: 30338828 [PubMed - in process]
We examined the clinical significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on the Glutaminase 1 gene (GLS1) expression. PATIENTS AND METHODS: 278 patients admitted to Qianfoshan Hospital Affiliated to Shandong University with osteosarcoma were randomly divided into the study group and the control group. Patients in the study group had 3-4 courses of cisplatin, ifosfamide, and adriamycin (DIA) chemotherapy before surgical excision, while no chemotherapy was used in the control group before the surgery. RESULTS: GLS1 expression in the study group decreased, the d...
CONCLUSIONS: We demonstrated that three-miRNA signature could be a potential biomarker for predicting clinical outcomes for BRCA patients. PMID: 30338807 [PubMed - in process]
Authors: Guo SJ, Zeng HX, Huang P, Wang S, Xie CH, Li SJ Abstract OBJECTIVE: Recently, studies have identified that microRNAs (miRNAs) are novel regulators for gene expression in tumor progression including breast cancer. The aim of the study is to investigate the clinical significance and underlying functions between miR-508-3p expression and triple-negative breast cancer (TNBC) development. PATIENTS AND METHODS: Quantitative Real-time PCR (QRT-PCR) was performed to determine the expression of miR-508-3p in 54 pairs of TNBC specimens and adjacent non-tumor tissues. The association between miR-508-3p expression...
CONCLUSIONS: The present study indicated that LINC01426 functioned as a tumor promoter and it might be a potential biomarker and therapeutic target in glioma. PMID: 30338804 [PubMed - in process]
CONCLUSIONS: We showed that lowly expressed microRNA-203 could promote the invasion and inhibit apoptosis of laryngeal cancer cells via inhibiting LASP1. PMID: 30338803 [PubMed - in process]
CONCLUSIONS: SBF2-AS1 might be considered as a novel molecule involved in HCC development, which provides a potential therapeutic target for HCC. PMID: 30338801 [PubMed - in process]
CONCLUSIONS: LINC00657 had a low expression in colon cancer tissues, which could accelerate cell proliferation and invasion by activating PI3K/AKT pathway and inhibiting CAPN7 expression. PMID: 30338799 [PubMed - in process]